Blood lipid profile and oxidative stress in patients suffering from peripheral vascular disease;Perfil lipídico y estado oxidativo en pacientes con enfermedad vascular periférica

Anales de Cirugia Cardiaca y Vascular

Volumn 11, Issue 3, 2005, Pages 124-128

  Fenollar, María ^a,b   Parra, Ma Soledad ^c   Albaladejo, Ma Dolores ^d   Cassinello, Norberto ^b  

^a HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^b UNIVERSITY OF MURCIA   (Spain)

^c UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^d UNIVERSITY OF ALICANTE   (Spain)

Author keywords

Autoantibodies against low density lipoprotein (OLAB); Oxidized low density lipopotein (ox LDL); Peripheral arterial disease (PAD)

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; HIGH DENSITY LIPOPROTEIN; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ARTERY DISEASE; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; HUMAN; INTERMITTENT CLAUDICATION; LIPOPROTEIN BLOOD LEVEL; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 25144442312     PISSN: 11352760     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Fontaine R, Kim M, Kieny R. Die chirurgische Behandlung der peripheren Durch-blutungsstörungen. Helvetia Chirurgica Acta 1954;5(6):199-533.
2. Pomrehn P, Duncan B, Weissfeld L, Wallace RB, Barnes R, Heiss G, et al. The association of dyslipoproteinemia with symptoms and signs of peripheral arterial disease: the lipids research clinics program prevalence study. Circulation 1986;73(Suppl I):I-100-I-107.
3. Hughson WG, Mann JI, Garrod A. Intermittent claudication: prevalence and risk factors. Br Med J 1978;11:1379-81.
4. Parra Pallarés S, Albaladejo Otón MD, Martínez Hernández P. Modificaciones cualitativas de las lipoproteínes. Anales de Medicina Interna 2000;17 (6):317-23.
5. Witzum JL. The oxidation hypothesis of atherosclerosis. Lancet 1994; 344: 793-795.
6. Ylä-Herttuala, Palinski SW, Rosenfeld ME, Parthasarathy S, Carew TE, Butler SW, Witzum JL and Steinberg D. Evidence for the presence of oxidatively modified LDL in atherosclerotic lesions of rabbit and man. J Clin Invest 1989;84:1086-95.
7. Shaw PX. Rethinking oxidized low-density lipoprotein, its role in atherogenesis and the immune responses associated with it. Arch Immunol Ther Exp (Warsz) 2004;52(4):225-39.
8. Witzum JL, Steinberg D. The oxidative modification hypothesis of atherosclerosis: does it hold for humans? Trends Cardiovasc Med 2001;11(3-4):93-102.
9. Stocker R, Keaney JF Jr. Role of oxidative modifications in atherosclerosis. Physiol Rev 2004;84(4):1381-478.
10. Smith I, Franks PJ, Greenhalg RM, Poulter NR, Powell JT. The influence of smoking cesation and hypertriglyceridemia on the progression of peripheral arterial disease and the onset of critical ischemia. Eur J Vasc Endovasc Surg 1996;72:513-8.
11. Gofin R. Kark JD, Friedlander Y, Lewis BS, Witt H, Stein Y, et al. Peripheral vascular disease in a middle-aged population sample. The Jerusalem Lipid Research Clinic Prevalence Study. Isr J Med Sci 1987;23:157-67.
12. Friedewald WT, Levy RJ, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.
13. Martínez-Hernández P, Fenollar-Cortés M, Albaladejo-Otón M, Parra-Pallarés S. Evaluation of a simple ultracentrifugation method to separate and quantificate plasmatic lipoproteins. Clin Chem 2002;48(6)S:A113.
14. Karen A Kramer, John F O'Brien, Josph P McConnell Mayo. Oxidized LDL Evaluation of an ELISA Method for Potential Use as a Marker of Cardiovascular Risk. Presented at the 2003 AACC Annual Meeting in Philadelphia. Rochester, MN, USA.: Clinic and Foundation, 2003.
15. Tatzer F, Wonisch W, Schmidl E, Esterbauer H. Quantitative determination of oLAb titers in various animal species. Biofactors 1997;6(2):125-30.
16. Waeg G, Dimsity G, Esterbauer H. Monoclonal antibodies for detection of 4-hydroxynonenal modified proteins. Free Radic Res 1996;25(2):149-59.
17. Zimmerman BR, Palumbo PJ, O'Fallon WM, Ellefson RD, Osmundson PJ, Kkazmier FJ. A prospective study of peripheral occlusive arterial disease in diabetes. III: initial lipid and lipoprotein findings. Mayo Clinic Proc 1981;6:233-242.
18. Pujia A, Gnasso A, Mancuso G, Spagnudo M, Cosco C, Cortese C, et al. Arteriopatia asintomatica dezli arti inferiori. Prevalenza e fattori di rischlo in una popolazione del sud Italia. Minerva Cardioangiol 1993; 41:13-138.
19. Kannel WB, McGee DL. Update on some epidemiological features of intermittent claudication. J Am Geriatr Soc 1985;33:13-8.
20. Kannel WB, Skinner JJ Jr, Schwartz MJ, Shurtleff D, et al. Intermittent claudication: incidince in the Framingham study. Circulation 1990;82:1925-31.
21. Shaw PX. Rethinking oxidized low-density lipoprotein, its role in atherogenesis and the inmune responses associated with it. Arch Immunol Ther Exp (Warsz). 2004;52(4):225-39.
22. Sigurdardottir V, Fagerberg B and Hulthe J. Circulating oxidized low-density lipoprotein (LDL) is associated with risk factors of the metabolic syndrome and LDL size in clinically healthy 58-year-old men (AIR study). Journal of Internal Medicine 2002;252:440-7.
23. Shoji T, Nishizawa Y, Fukumoto M, Shimamura K, Kmura J, Kanda H, Emoto M, Kawaagshi T, Morii H. Inverse relationship between circulating oxidized low density lipoprotein(oxLDL) and anti-oxLDL antibody levels in healthy subjects. Atherosclerosis 2000;148 (1):171-7.
24. Itabe H. Atherosclerosis and sensitive determination of oxidized LDL using monoclonal antibody. Yakugaku Zassh 2002;122(10):745-53.